1. HealthCanada. Important drug safety information until further information is available, Paxil® (paroxetine hydrochloride) should not be used in children and adolescents under 18 years of age. 2003. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2003/paxil_hpc-cps-eng.php . Accessed 5 April 2011.
2. Medicines CoSo. Safety of Seroxat (Paroxetine) in children and adolescents under 18 years-contraindication in the treatment of depressive illness. 2003. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2015704 . Accessed 13 June 2011.
3. Administration FaD. Reports of Suicidality in Pediatric Patients Being Treated with Antidepressant Medications for Major Depressive Disorder (MDD). 2003. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm168828.htm . Accessed 15 June 2011.
4. Administration FaD. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. 2004. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm . Accessed 15 June 15 2011.
5. Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, Sareen J. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. [Erratum appears in CMAJ. 2008 May 20;178(11):1466]. CMAJ. 2008;178(8):1005–11.